SCHEMBL874274

SCHEMBL874274

O=C(Nc1ccc(F)cc1)Nc1ccc(S(=O)(=O)C(CCn2nnc3ccccc3c2=O)C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.48
MMP9 P14780 2/20 0.48
GPR139 Q6DWJ6 1/20 0.46
KMT2A Q03164 5/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP13 P45452 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875318 0.92 KMT2A (0.46) MMP2MMP9GPR139KMT2AKDM4E
SCHEMBL878059 0.91 GPR139 (0.46) GPR139KMT2AMEN1ALDH1A1HTT
SCHEMBL874492 0.87 KMT2A (0.49) MMP2MMP9KMT2AKDM4EMEN1
SCHEMBL875418 0.87 KMT2A (0.45) MMP2MMP9GPR139KMT2AKDM4E
SCHEMBL877407 0.86 CA12 (0.48) MMP2MMP9GPR139KMT2AMEN1
SCHEMBL874237 0.85 SMN1; SMN2 (0.53) MMP2MMP9GPR139KMT2AKDM4E
SCHEMBL877249 0.85 ALDH1A1 (0.47) MMP2MMP9KMT2AKDM4EMEN1
SCHEMBL878191 0.83 ALDH1A1 (0.49) MMP2MMP9GPR139KMT2AKDM4E
SCHEMBL878119 0.83 ALDH1A1 (0.49) KMT2AKDM4EMEN1ALDH1A1HTT
SCHEMBL874387 0.83 KMT2A (0.48) GPR139KMT2AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 MMP2 17/4885MMP9 1/4885GPR139 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.